IFWE use deep learning on neuro-imaging can we detect earlier and optimize diagnostic time and quality?

​​​​​​​​​​​​​​

WHAT CHALLENGE DOES BRAINSIGHT.AI ADDRESS ?

Neuro-psychiatric disorders is the second largest contributor to global burden disease. 

Current tools do not capture important patient information, that can help in early screening, diagnosis and modeling.

BrainSight.AI works with AI technologies which today has the potential to significantly enable a more holistic view of patient for better outcomes. BrainSight.AI using Neuro-biological and digital data can help to reduce diagnostic complexity and aid psychiatrists to scale their diagnostics. BrainSight.AI is the only company providing such a disruptive, comprehensive solution.

DISCOVER BRAINSIGHT.AI’S BREAKTHROUGH INNOVATION

BrainSight.AI founded by Laina Emmanuel and Rimjhim Agrawal creates AI-based diagnostic tools that can help in functional investigation of the brain. This can aid psychiatrists and neurologists in diagnosing  mental  disorders  using  MRI  scans, and neurosurgeons in pre-surgical planning, especially for comatose and cognitively challenged patients.  The AI-powered software empowers doctors with functional reports in a matter of hours.

The tool uses AI-based  imaging  markers  to  identify  and  classify  disorders,  such  as  schizophrenia, bipolar disorder, and early forms of dementia, and simulate effects of surgery on brain functionality. BrainSight.AI is pilot testing their prototype with two hospital chains, including the largest private hospital chain in India.

HOW DOES THE 3DEXPERIENCE LAB HELP BRAINSIGHT.AI ?

CELLINK joined the 3DEXPERIENCE Lab in 2020

3DEXPERIENCE Lab open innovation laboratory and accelerator program is helping BrainSight.AI, an Indian startup in neuroscience, in its efforts to revolutionize the diagnosis and prognosis of neuro-psychiatric disorders using artificial intelligence. The BrainSight.AI MRI solutions for functional and structural investigation give an unprecedented view into the patient, enabling early screening, diagnosis and modeling. It combines AI and neuroscience to enable greater precision in neurological and psychiatric investigation for accelerated patient outcomes. 

BrainSight.AI is using BIOVIA and SIMULIA solutions to create a world-class next generation pipeline where data from clinical trials and real world evidence from hospitals can feed into research and discovery of precision medicine. It is enabling psychiatrists to leverage simulation technology to forecast challenges and outcomes for disorders such as schizophrenia, bipolar disorder and dementia. With SIMULIA applications, the team envisages the potential to develop actionable 3D visualization reports with comprehensive insights for offline consultation. Through simulation of prognosis, doctors can easily develop a medication and therapy impact on the ailing patients. 

BRAINSIGHT.AI’S SUSTAINABLE DEVELOPMENT GOALS 🌍

KEY FACTS